Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Summit Therapeutics Inc (SMMT) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance

Summit Therapeutics IncTrade
NEOS S&P 500 High Income ETFTrade

Price performance (Past 24H)

Key statistics

Summit Therapeutics Inc vs NEOS S&P 500 High Income ETF — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while NEOS S&P 500 High Income ETF trades at $53.45. The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

SMMTSPYI
Market Cap
$10.48B
Sector
HealthIncome / Options Overlay
52-Week High
$29.32$54.07
52-Week Low
$13.05$47.98
Enterprise Value
$9.90B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT

About NEOS S&P 500 High Income ETF

SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.

Read more on SPYI